INO Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -10571.43%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat AIM ImmunoTech's return on equity of -256.33%.

Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 277.89%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe AIM ImmunoTech is more attractive than Inovio Pharmaceuticals, Inc..

Inovio Pharmaceuticals, Inc. has a beta of 1.544, which suggesting that the stock is 54.377% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 448.96x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Arcturus Therapeutics Holdings, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -95.02%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98%.

Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 277.89%. On the other hand Arcturus Therapeutics Holdings, Inc. has an analysts' consensus of $35.50 which suggests that it could grow by 438.7%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Inovio Pharmaceuticals, Inc..

Inovio Pharmaceuticals, Inc. has a beta of 1.544, which suggesting that the stock is 54.377% more volatile than S&P 500. In comparison Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, suggesting its more volatile than the S&P 500 by 110.246%.

Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings, Inc. pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Arcturus Therapeutics Holdings, Inc. quarterly revenues of $14.2M. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Arcturus Therapeutics Holdings, Inc.'s PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 448.96x versus 2.10x for Arcturus Therapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Capricor Therapeutics, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -63.94%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Capricor Therapeutics, Inc.'s return on equity of -77.32%.

Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 277.89%. On the other hand Capricor Therapeutics, Inc. has an analysts' consensus of $20.70 which suggests that it could fall by -30.91%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Capricor Therapeutics, Inc..

Inovio Pharmaceuticals, Inc. has a beta of 1.544, which suggesting that the stock is 54.377% more volatile than S&P 500. In comparison Capricor Therapeutics, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.632%.

Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Capricor Therapeutics, Inc. pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Capricor Therapeutics, Inc. quarterly revenues of --. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Capricor Therapeutics, Inc.'s net income of -$24.6M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Capricor Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 448.96x versus 122.18x for Capricor Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of 13.19%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 277.89%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 539.54%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Inovio Pharmaceuticals, Inc..

Inovio Pharmaceuticals, Inc. has a beta of 1.544, which suggesting that the stock is 54.377% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 448.96x versus 2.19x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.